The NHS has announced a significant operational efficiency gain with the introduction of a new injectable form of pembrolizumab, an immunotherapy treatment that reduces administration time from approximately two hours to under two minutes per patient session. The advancement will affect thousands of cancer patients across England while simultaneously freeing substantial clinical capacity within the health service.
The injectable pembrolizumab works by blocking a protein called PD-1, which acts as a brake on immune responses, enabling the immune system to recognise and attack cancer cells. The treatment represents a marked improvement over the previous intravenous drip version, which required administration in a specialist clean room with significant preparation overhead for NHS staff.
Operational Efficiency and Resource Liberation
The efficiency gains are substantial. The NHS estimates the new treatment will save more than 100,000 hours of preparation and treatment time annually. Patients will receive the injectable either as a one-minute injection every three weeks or a two-minute injection every six weeks, compared to the previous two-hour sessions required for intravenous administration.
Most of the 14,000 patients currently taking pembrolizumab are expected to transition to the new injectable version. This transition directly addresses a critical constraint within NHS operations: appointment capacity and staff time allocation. By reducing per-patient treatment duration by approximately 98 percent, the service can redirect freed clinical resources toward treating additional patients and reducing waiting times—a persistent challenge within the health system.
Prof Peter Johnson, the NHS national clinical director for cancer, stated: "This immunotherapy offers a lifeline for thousands of patients and it's fantastic that this new rapid jab can now take just a minute to deliver – meaning patients can get back to living their lives rather than spending hours in a hospital chair. Managing cancer treatment and regular hospital trips can be really exhausting, and not only will this innovation make therapy much quicker and more convenient for patients, it will help free up vital appointments for NHS teams to treat more people and continue to bring down waiting times."
Expanding Treatment Options
The new injectable pembrolizumab joins nivolumab, another immunotherapy injection that takes three to five minutes to administer, for which up to 15,000 cancer patients became eligible one year ago. Combined, these two immunotherapies are now available for almost 30 types of cancer on the NHS, expanding treatment options across a broad patient population.
James Richardson, the national specialty adviser for cancer drugs at NHS England, characterized the development as mutually beneficial: "This is a win-win innovation, because patients will spend far less time in hospital and, crucially, our clinical teams will have more capacity to care for others. The time saved through this change is a huge gain for the NHS, and demonstrates how we are continuing to modernise cancer care for the benefit of patients."
Patient Experience
Sharley Xerxes, an 89-year-old from St Albans, was among the first patients to receive the new treatment on the NHS. "I can't believe how little time it took," she said. "I was only in the chair for a matter of minutes instead of an hour or more. It's made such a difference and gives me more time to live my life, including spending more time gardening."
University Hospitals Bristol and Weston NHS Foundation Trust and the East and North Hertfordshire Teaching NHS Trust will be among the first NHS facilities in England to provide the treatment.
Why This Matters:
This development illustrates how technological advancement and process improvement can address resource constraints within publicly funded healthcare systems without requiring increased budget allocation. The 100,000-hour annual time savings represents genuine operational efficiency—clinical staff hours that can be redirected toward expanding treatment capacity and reducing patient waiting times. For individual patients, the reduction from two-hour sessions to one-to-two-minute injections eliminates a significant burden on daily life while maintaining therapeutic efficacy. The expansion of immunotherapy options across 30 cancer types demonstrates how pharmaceutical innovation expands treatment possibilities within existing institutional frameworks. From a healthcare system perspective, this efficiency gain addresses a fundamental challenge: delivering more care with existing resources. The injectable format also reduces infrastructure requirements—eliminating the need for specialist clean rooms for each administration—further reducing operational costs and complexity.